P591 A prospective controlled pilot study of faecal microbiota transplantation for chronic refractory pouchitis

Landy, Jonathan; Al-Hassi, Hafid O.; Ronde, E.; Mann, Erika; Peake, S.; McLaughlin, Simon D.; Perry−Woodford, Zarah L; Ciclitira, Paul J.; Nicholls, R. J.; Clark, SK; Knight, SC; Hart, Ailsa

doi:10.1016/s1873-9946(13)60612-1

Cited by 9 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pinn et al [57] did not describe criteria for the diagnoses of IBS and included patients with diarrhea-predominant, constipationpredominant and IBS patients with alternating stool pattern. Landy at al [9] confirmed chronic refractory pouchitis clinically, endoscopically and histologically. Borody et al [58] defined chronic constipation as a stool frequency of once every four to seven days associated with symptoms.…”

Section: Risk Of Bias Within Studiesmentioning

confidence: 90%

“…A total number of 1029 patients underwent FMT. The clinical efficacy of FMT was assessed in patients with: CDI [2, (n = 883), IBD [5,[51][52][53][54][55][56] (n = 112), IBS [57] (n = 13), pouchitis [9] (n = 8), constipation [58] (n = 3) and metabolic syndrome [10] (n = 10 randomised to the donor feces arm). Age of the included patients varied widely from 6 to 94 years.…”

Section: Patients Treatment Information and Donor Screeningmentioning

confidence: 99%

“…Pinn et al [57] treated 13 IBS patients, resolution or WJG|www.wjgnet.com Table 3 Treatment information improvement of symptoms was reported in 70%, including abdominal pain (72%), bowel habit (69%), dyspepsia (67%), bloating (50%), and flatus (42%). Eight pouchitis patients were treated by Landy et al [9] , none of these patients achieved clinical remission after FMT measured by the pouch disease activity index, but two patients demonstrated a change to a ciprofloxacin sensitive bacteria following FMT. In a series of 18 male subjects diagnosed with a metabolic syndrome there was a statistically significant increase in peripheral insulin sensitivity measured by Hyperinsulinemic-Euglycemic Clamp (median rate of glucose disappearance changed from 26.2 to 45.3 μmol/kg per minute; P < 0.05) of recipients treated with donor feces compared to placebo [10] .…”

Section: Fmt In Other Indicationsmentioning

confidence: 99%

“…Since that time several case series on FMT have been published mainly on refractory and recurrent Clostridium difficile infection (CDI), but also for other intestinal diseases such as ulcerative colitis (UC) and irritable bowel syndrome (IBS) [3][4][5][6] . From the 1990's FMT has been reported in chronic constipation, Crohn's disease (CD), pouchitis, metabolic syndrome, chronic fatigue syndrome, idiopathic thrombocytopenic purpura and even in multiple sclerosis [7][8][9][10][11][12][13] . By performing a systematic review we aimed to provide a comprehensive assessment of the efficacy and safety of fecal microbiota transplantation used as clinical therapy for various diseases and pre-clinical conditions.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review

Rossen

MacDonald

Vries

et al. 2015

WJG

211

131

View full text Add to dashboard Cite

AIM:To study the clinical efficacy and safety of Fecal microbiota transplantation (FMT). We systematically reviewed FMT used as clinical therapy. METHODS:We searched MEDLINE, EMBASE, the Cochrane Library and Conference proceedings from inception to July, 2013. Treatment effect of FMT was calculated as the percentage of patients who achieved clinical improvement per patient category, on an intention-to-treat basis. RESULTS:We included 45 studies; 34 on Clostridium difficile -infection (CDI), 7 on inflammatory bowel disease, 1 on metabolic syndrome, 1 on constipation, 1 on pouchitis and 1 on irritable bowel syndrome (IBS). In CDI 90% resolution of diarrhea in 33 case series (n = 867) was reported, and 94% resolution of diarrhea after repeated FMT in a randomized controlled trial (RCT) (n = 16). In ulcerative colitis (UC) remission rates of 0% to 68% were found (n = 106). In Crohn's disease (CD) (n = 6), no benefit was observed. In IBS, 70% improvement of symptoms was found (n = 13). 100% Reversal of symptoms was observed in constipation (n = 3). In pouchitis, none of the patients (n = 8) achieved remission. One RCT showed significant improvement of insulin sensitivity in metabolic syndrome (n = 10). Serious adverse events were rare. SYSTEMATIC REVIEWS CONCLUSION:FMT is highly effective in CDI, and holds promise in UC. As for CD, chronic constipation, pouchitis and IBS data are too limited to draw conclusions. FMT increases insulin sensitivity in metabolic syndrome.

show abstract

Section: Risk Of Bias Within Studiesmentioning

confidence: 90%

Section: Patients Treatment Information and Donor Screeningmentioning

confidence: 99%

Section: Fmt In Other Indicationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review

Rossen

MacDonald

Vries

et al. 2015

WJG

211

131

View full text Add to dashboard Cite

show abstract

“…Sin embargo, a los 18 meses, y a pesar del entusiasmo inicial, sufrió una recaída que requirió la reintroducción del tratamiento farmacológico 23 . Hasta la fecha se han publicado 13 casos más a nivel mundial de enfermedad de Crohn en los que el TMF fracasó 84,93,94 .…”

Section: Trasplante De Microbiota Fecal En La Enfermedad Inflamatoriaunclassified